Dr. Liu Xun, CEO of Taichu Group, led the company's team to Boston to attend this year's BIO Conference.

On November 11, 2024, Shanghai Taichu Biotechnology Co., Ltd. received the updated "Drug GLP Certification Certificate" issued by the NMPA. This certification adds three new accredited items to the company's existing qualifications, including single and repeated dose toxicity studies in monkeys.

Taichu Bio achieving Full AAALAC Accreditation for its animal welfare program.

Taichu Group made a remarkable appearance at the 2024 BIO convention, gathering with both long-standing partners and new acquaintances. Participants shared Taichu Group's achievements and progress in various areas of drug development.

Looking at Ma Jing's CV, the dominant theme is clearly "safety evaluation" and "toxicology." Yet, before she specialized in tox, she spent eleven years teaching pharmacology at a medical college. "Once I moved into toxicology, I never looked back," she reflects on her career pivot. She readily admits that the field was a perfect fit—a discipline worthy of her lifelong dedication.

AceMab, a JV company of Taichu Group, has been granted authorization by the China National Intellectual Property Administration (CNIPA) for its invention patent titled "Recombinant Genome, Non-Human Mammalian Cells and Methods and Uses for Their Production".

Taichu Bio was awarded the "Drug GLP Certification Certificate" by the National Medical Products Administration (NMPA) on January 19, 2024.